Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Zai Lab To Present Findings From Preclinical Studies Highlighting ZL-1310, A Novel Antibody-Drug Conjugate (ADC) For Treatment Of Solid Tumors

Author: Benzinga Newsdesk | March 14, 2024 02:38am

ZL-1310 is an innovative ADC targeting DLL3, a promising therapeutic target in small cell lung cancer and other DLL3+ solid tumors
Data will be shared in a poster presentation at the European Lung Cancer Congress 2024 (ELCC 2024)

Posted In: ZLAB